Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind rituximab trial in ME/CFS (Japan)
jRCT2031240192Phase 2Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myalgic encephalomyelitis (ME) comparing Rituximab pretreatment group with Placebo pretreatment group (2 arms). Primary endpoint: Improvement rate in ME/CFS severity (MHLW PS). Started Apr 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on jRCT2031240192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240192.